No Data
No Data
The Analyst Verdict: Mersana Therapeutics In The Eyes Of 5 Experts
5 analysts have shared their evaluations of Mersana Therapeutics (NASDAQ:MRSN) during the recent three months, expressing a mix of bullish and bearish perspectives.The following table encapsulates the
Express News | JP Morgan Upgrades Mersana Therapeutics to Neutral, Announces $5 Price Target
12 Health Care Stocks Moving In Friday's After-Market Session
GainersCue Health (NASDAQ:HLTH) shares increased by 12.1% to $0.22 during Friday's after-market session. The company's market cap stands at $34.8 million. As per the press release, Q4 earnings came ou
AVLX, SGH and ETNB Are Among Pre Market Losers
Mersana Therapeutics (MRSN) Gets a Buy From Truist Financial
Top 10 Best Performing Biotech Stocks of 2024 so Far
No Data